# Right Ventricular Dysfunction in Tetralogy of Fallot: Inhibition of the Renin-angiotensin-aldosterone System

Study · id `cardio:ct-nct02010905` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02010905](<https://clinicaltrials.gov/study/NCT02010905>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02010905

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 120 participants.

## Technical summary

Registry record NCT02010905. Randomized; quadruple masking; primary purpose treatment. Start 2013-12 (registry gives no type); primary completion 2018-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 120 participants (planned count; ClinicalTrials.gov record NCT02010905, source copy `cardio:ctgov-nct02010905-2015-12-22`, retrieved 2026-10-26)
- Start date: 2013-12 (registry gives no type) (ClinicalTrials.gov record NCT02010905, source copy `cardio:ctgov-nct02010905-2015-12-22`, retrieved 2026-10-26)
- Primary completion: 2018-01 (anticipated) (ClinicalTrials.gov record NCT02010905, source copy `cardio:ctgov-nct02010905-2015-12-22`, retrieved 2026-10-26)
- Completion: 2018-01 (anticipated) (ClinicalTrials.gov record NCT02010905, source copy `cardio:ctgov-nct02010905-2015-12-22`, retrieved 2026-10-26)
- Countries: Netherlands (ClinicalTrials.gov record NCT02010905, source copy `cardio:ctgov-nct02010905-2015-12-22`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02010905-2015-12-22`, retrieved 2026-10-26)

## The registry's words

- Brief title: Right Ventricular Dysfunction in Tetralogy of Fallot: Inhibition of the Renin-angiotensin-aldosterone System
- Acronym: Redefine
- Condition: Tetralogy of Fallot
- Condition: Heart Defects, Congenital
- Condition: Ventricular Dysfunction, Right
- Intervention (Drug): Losartan
- Intervention (Drug): Placebo
- Lead sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Lead sponsor class: OTHER
- Collaborator: The Interuniversity Cardiology Institute of the Netherlands
- Collaborator class: OTHER\_GOV

## Connected pages

- Registry condition terms include this condition: Adult congenital heart disease (`cardio:adult-congenital-heart-disease`)
- Registry condition terms include this condition: Congenital heart disease (`core:congenital-heart-disease`)
- Registry intervention name matches this record: Losartan (`cardio:losartan`)
- Registry intervention is a member of this class by a sourced record link: Angiotensin receptor blockers (ARBs) (`cardio:angiotensin-receptor-blockers-arbs`)
- Registry lists this organization as the lead sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (`cardio:org-academisch-medisch-centrum-universiteit-van-amsterdam-amc-662d32`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effect of Losartan on Right Ventricular Dysfunction: Results From the Double-Blind, Randomized REDEFINE Trial (Right Ventricular Dysfunction in Tetralogy of Fallot: Inhibition of the Renin-Angiotensin-Aldosterone System) in Adults With Repaired Tetralogy of Fallot (`cardio:pubmed-29222139`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 800f9d22a63ae876c4fb45e697613f7d1438efe226e5dd081130ebd4f600cc02
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
